Effect of Piceatannol in Human Monocyte-Derived Dendritic Cells In Vitro
| Autor: | Akemi Umeyama, Shigenobu Arihara, Hitoshi Matsumoto, Masao Takei |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Lipopolysaccharides
T-Lymphocytes medicine.medical_treatment Fluorescent Antibody Technique Pharmaceutical Science chemical and pharmacologic phenomena Monocytes chemistry.chemical_compound Immune system Cancer immunotherapy Stilbenes medicine Humans CD86 Piceatannol business.industry Monocyte Antibodies Monoclonal Cell Differentiation hemic and immune systems Dendritic Cells T-Lymphocytes Helper-Inducer Dendritic cell Interleukin-12 Coculture Techniques Culture Media Cell biology Phenotype Cytokine medicine.anatomical_structure chemistry Immunology Cytokines Lymphocyte Culture Test Mixed business Platelet Aggregation Inhibitors CD80 |
| Zdroj: | Journal of Pharmaceutical Sciences. 94:974-982 |
| ISSN: | 0022-3549 |
| DOI: | 10.1002/jps.20279 |
| Popis: | Piceatannol is an anti-inflammatory, immunomodulatory, and antiproliferative stilbene that has been shown to interfere with the cytokine signaling pathway. Dendritic cells (DCs) play a pivotal in the initiation of T-cell–mediated immune responses, making them an attractive cellular adjuvant for use in cancer vaccines. This study investigated the effect of piceatannol on the phenotypic and functional maturation of human monocyte-derived DCs in vitro . Human monocytes were cultured with GM-CSF and IL-4 for 6 days, followed by another 2 days in the presence of piceatannol or LPS. DCs harvested on day 8 were examined using functional assays. The expression levels of CD1a, CD80, CD83, and CD86 as expressed by mean fluorescence intensity (MFI) on DCs differentiated from immature DCs after culture with 1 μM of piceatannol for 2 days were enhanced and decreased endocytic activity. Piceatannol-treated DCs also displayed enhanced T-cell stimulatory capacity in a MLR, as measured by T-cell proliferation. Similar results were obtained with DCs differentiated with LPS from immature DCs. However, piceatannol did not inhibit phenotypic and functional maturation induced by LPS from immature DCs. Piceatannol-treated DCs induced the differentiation of naive T cells towards a helper T-cell type 1 (Th1) response at DCs/T (1:5) cells ratio depending on IL-12 secretion. These results demonstrate that piceatannol may be used on DC-based vaccine for cancer immunotherapy. © 2005 Wiley-Liss, Inc. and the American Pharmacists Association |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text